Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback